ABIONYX Pharma Statistics

Total Valuation

ABIONYX Pharma has a market cap or net worth of EUR 44.46 million. The enterprise value is 43.98 million.

Market Cap	44.46M
Enterprise Value	43.98M

Important Dates

The next estimated earnings date is Thursday, September 25, 2025.

Earnings Date	Sep 25, 2025
Ex-Dividend Date	n/a

Share Statistics

ABIONYX Pharma has 34.68 million shares outstanding. The number of shares has increased by 14.80% in one year.

Current Share Class	34.68M
Shares Outstanding	34.68M
Shares Change (YoY)	+14.80%
Shares Change (QoQ)	+7.62%
Owned by Insiders (%)	32.62%
Owned by Institutions (%)	4.73%
Float	21.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.77
PB Ratio	5.92
P/TBV Ratio	21.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-10.04
EV / Sales	9.66
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.88

Financial Position

The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.37.

Current Ratio	1.58
Quick Ratio	1.49
Debt / Equity	0.37
Debt / EBITDA	n/a
Debt / FCF	-0.74
Interest Coverage	-120.68

Financial Efficiency

Return on equity (ROE) is -56.76% and return on invested capital (ROIC) is -25.86%.

Return on Equity (ROE)	-56.76%
Return on Assets (ROA)	-19.67%
Return on Invested Capital (ROIC)	-25.86%
Return on Capital Employed (ROCE)	-45.39%
Revenue Per Employee	89,235
Profits Per Employee	-85,902
Employee Count	51
Asset Turnover	0.32
Inventory Turnover	17.16

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.87% in the last 52 weeks. The beta is 1.02, so ABIONYX Pharma's price volatility has been similar to the market average.

Beta (5Y)	1.02
52-Week Price Change	+3.87%
50-Day Moving Average	1.23
200-Day Moving Average	1.26
Relative Strength Index (RSI)	57.56
Average Volume (20 Days)	28,224

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABIONYX Pharma had revenue of EUR 4.55 million and -4.38 million in losses. Loss per share was -0.13.

Revenue	4.55M
Gross Profit	844,000
Operating Income	-4.47M
Pretax Income	-4.38M
Net Income	-4.38M
EBITDA	-4.34M
EBIT	-4.47M
Loss Per Share	-0.13

Full Income Statement

Balance Sheet

The company has 3.24 million in cash and 2.76 million in debt, giving a net cash position of 478,000 or 0.01 per share.

Cash & Cash Equivalents	3.24M
Total Debt	2.76M
Net Cash	478,000
Net Cash Per Share	0.01
Equity (Book Value)	7.52M
Book Value Per Share	0.22
Working Capital	2.15M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.63 million and capital expenditures -68,000, giving a free cash flow of -3.70 million.

Operating Cash Flow	-3.63M
Capital Expenditures	-68,000
Free Cash Flow	-3.70M
FCF Per Share	-0.11

Full Cash Flow Statement

Margins

Gross margin is 18.55%, with operating and profit margins of -98.11% and -96.26%.

Gross Margin	18.55%
Operating Margin	-98.11%
Pretax Margin	-96.26%
Profit Margin	-96.26%
EBITDA Margin	-95.36%
EBIT Margin	-98.11%
FCF Margin	n/a

Dividends & Yields

ABIONYX Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.80%
Shareholder Yield	n/a
Earnings Yield	-9.85%
FCF Yield	-8.33%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABIONYX Pharma has an Altman Z-Score of 3.01.

Altman Z-Score	3.01
Piotroski F-Score	n/a